Article
Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
Medical oncology (Northwood, London, England) - 1 Mar 2015
Tamiya Akihiro, Tamiya Motohiro, Shiroyama Takayuki, Saijo Nobuhiko, Nakatani Takeshi, Minomo Shojiro, Tsuji Taisuke, Takeuchi Naoko, Omachi Naoki, Kurata Kanako, Suzuki Hidekazu, Okamoto Norio, Okishio Kyoichi, Hirashima Tomonori, Atagi Shinji
Abstract excerpt
Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is an effective treatment for advanced non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations. However, there have been little evidence-based studies of gefitinib in combination with platin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.